HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE COVER ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Submit a letter to the editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Macdonald, J. S. Search for Related Content PubMed PubMed Citation Articles by Macdonald, J. S.

CA: A Cancer Journal for Clinicians, Vol 49, Issue 4 202-219, Copyright © 1999 by American Cancer Society

ARTICLES

Adjuvant therapy of colon cancer

J. S. Macdonald
Gastrointestinal Oncology Service, Saint Vincents Comprehensive Cancer Center, New York, NY, USA.

Adjuvant therapy, believed by some to be of no benefit for colorectal cancer as recently as 10 years ago, now offers thousands of patients considerable hope after surgical resection. The first effective adjuvant regimen--combined fluorouracil (5-FU) and levamisole--described in 1989, was soon supplanted by a variety of 5-FU-based regimens, usually combined with leucovorin. Although most recent research in the adjuvant setting has focused on refining chemotherapy doses, schedules, and combinations, with the aim of improving efficacy and decreasing toxicity, investigators have also explored other approaches, such as portal vein infusion, monoclonal antibodies, interferon-alpha, and vaccines. Future directions being evaluated for adjuvant therapy of colon cancer include the use of oral fluorinated pyrimidines, which may replace current intravenous treatments, as well as the incorporation of new agents, such as oxaliplatin and CPT-11, into adjuvant chemotherapy programs.

This article has been cited by other articles:

				B. M. Wolpin, J. A. Meyerhardt, H. J. Mamon, and R. J. Mayer Adjuvant Treatment of Colorectal Cancer CA Cancer J Clin, May 1, 2007; 57(3): 168 - 185. [Abstract] [Full Text] [PDF]

				J. M. Ford and A. S. Whittemore Predicting and preventing hereditary colorectal cancer. JAMA, September 27, 2006; 296(12): 1521 - 1523. [Full Text] [PDF]

				U. H. Frey, H. Alakus, J. Wohlschlaeger, K. J. Schmitz, G. Winde, H. G. van Calker, K.-H. Jockel, W. Siffert, and K. W. Schmid GNAS1 T393C Polymorphism and Survival in Patients with Sporadic Colorectal Cancer Clin. Cancer Res., July 15, 2005; 11(14): 5071 - 5077. [Abstract] [Full Text] [PDF]

				H. Hurwitz New Combinations in Metastatic Colorectal Cancer: What Are Our Expectations? Oncologist, May 1, 2005; 10(5): 320 - 322. [Full Text] [PDF]

				S. Gill, C. L. Loprinzi, D. J. Sargent, S. D. Thome, S. R. Alberts, D. G. Haller, J. Benedetti, G. Francini, L. E. Shepherd, J. Francois Seitz, et al. Pooled Analysis of Fluorouracil-Based Adjuvant Therapy for Stage II and III Colon Cancer: Who Benefits and by How Much? J. Clin. Oncol., May 15, 2004; 22(10): 1797 - 1806. [Abstract] [Full Text] [PDF]

				P. Jantscheff, L. Terracciano, A. Lowy, K. Glatz-Krieger, F. Grunert, B. Micheel, J. Brummer, U. Laffer, U. Metzger, R. Herrmann, et al. Expression of CEACAM6 in Resectable Colorectal Cancer: A Factor of Independent Prognostic Significance J. Clin. Oncol., October 1, 2003; 21(19): 3638 - 3646. [Abstract] [Full Text] [PDF]

				F. Graziano and S. Cascinu Prognostic molecular markers for planning adjuvant chemotherapy trials in Dukes' B colorectal cancer patients: how much evidence is enough? Ann. Onc., July 1, 2003; 14(7): 1026 - 1038. [Abstract] [Full Text] [PDF]

				T. Watanabe, T.-T. Wu, P. J. Catalano, T. Ueki, R. Satriano, D. G. Haller, A. B. Benson, and S. R. Hamilton Molecular Predictors of Survival after Adjuvant Chemotherapy for Colon Cancer N. Engl. J. Med., April 19, 2001; 344(16): 1196 - 1206. [Abstract] [Full Text] [PDF]